You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

Kedrion alongside IPOPI at the IPIC Congress in Madrid

The importance of early diagnosis and the most recent innovations in the treatment of PID patients were the focus

read more 

EVENTS

Kedrion keeps Hemophilia therapy debate flowing in Latin America

A recent CLAHT Congress symposium restates current and future role of replacement therapy

read more 

CORPORATE

FSI SGR enters Kedrion share capital

The company continues with its growth and development strategy

read more 

  1. CORPORATE - 24-03-2017

    New company AO Kirov Plasma established in Russia

    It’s a joint venture between Kedrion Biopharma, Nacimbio and Pharmastandard

    read more 

  2. PLASMA & BIOTHERAPIES - 22-03-2017

    Article by Prof. Farrugia and Daniela Scaramuccia published on “Biologicals”

    International medical journal hosts review of contract plasma fractionation dynamics

    read more 
  3. Kedrion - Feature thumbnail

    CORPORATE - 28-12-2016

    Kedrion Biopharma strengthens its presence in Russia

    Memorandum of Understanding with Russian pharmaceutical companies for a joint plasma products manufacturing program

    read more 

  4. PLASMA & BIOTHERAPIES - 08-11-2016

    FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin

    Announcement by Kedrion Biopharma and Kamada. Regulatory decision expected in August 2017

    read more 

Pages

For more information please contact: pressoffice@kedrion.com